Shutdown, Tariffs, Pharma Pricing Make for a Busy Start to the Quarter. What Matters.

Group 1 - The government shutdown has commenced, impacting various sectors and potentially leading to economic uncertainty [1] - Pfizer's recent drug pricing deal may set a precedent for the pharmaceutical industry, influencing future pricing strategies and negotiations [1] - There are ongoing risks associated with Trump's tariffs, which could affect trade dynamics and cost structures for companies across multiple industries [1]